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Abstract
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The emergence of multidrug-resistant bacterial and fungal strains poses a threat to human health
that requires the design and synthesis of new classes of antimicr obial agents. We evaluated bis(Namidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones for their antibacterial and antifungal
activities against panels of Gram-positive/Gram-negative bacteria as well as fungi. We investigated
their potential to develop resistance against both bacteria and fungi by a multi-step, resistanceselection method, explored their potential to induce the production of reactive oxygen species, and
assessed their toxicity. In summary, we found that these compounds exhibited broad-spectrum
antibacterial and antifungal activities against most of the tested strains with minimum inhibitory
concentration (MIC) values ranging from <0.5->500 μM against bacteria and 1.0->31.3 μg/mL
against fungi; and in most cases, they exhibited either superior or similar antimicrobial activity
compared to those of the standard drugs used in the clinic. We also observed minimal emergence
of drug resistance to these newly synthesized compounds by bacteria and fungi even after 15
passages, and we found weak to moderate inhibition of the human Ether-à-go-go-related gene
(hERG) channel with acceptable IC50 values ranging from 1.12-3.29 μM. Overall, these studies sh
ow that bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones are potentially
promising scaffolds for the discovery of novel antibacterial and antifungal agents.
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1. Introduction
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The emergence of multidrug-resistant bacteria and fungi as human pathogens warrants a
continued focus on the development of new pharmacophores for the treatment of these
devastating and often fatal infections. The rise of multidrug-resistant bacteria, such as
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci
(VRE), adversely affects the efficacy of many known, standard-of-care, antibacterial agents.1
Evidence of the impact of these multidrug-resistant strains appears in a 2011 report from the
Centers for Disease Control and Prevention (CDC) that estimates that the national incidence
of invasive MRSA infections was 80,461 cases and 650 deaths. This mortality rate is among
the highest recorded for bacterial infections.2 Likewise, listerosis, which is a common
foodborne illness caused by Listeria monocytogenes, represents a serious illness afflicting
elderly people, newborns, and those with impaired immune systems. Estimates are that 19%
of deaths associated with the consumption of contaminated foods in the United States are
due to L. monocytogenes.3

Author Manuscript

The incidence of invasive fungal infections is also on the rise due to an increasing population
of critically ill patients as a result of the human immunodeficiency virus (HIV), systemic
diseases such as cancer, and the increasing occurrence of organ transplantation.4 The
National Healthcare Safety Network (NHSN) at the CDC reported that Candida spp. ranked
fifth amongst hospital-acquired pathogens.5 Candida spp. are reported as the fourth most
common causative pathogens of nosocomial and of fatal bloodstream infections.6 Eukaryotic
C. albicans shares a close evolutionary relationship, as well as many cellular mechanisms,
with their human hosts, and represents challenges for treatment of systemic fungal
infections. There is a clear need for new antimicrobials that selectively inhibit these
microorganisms without causing host toxicity.
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Pentamidine represents an archetypical, biscationic antibiotic with a symmetrical structure
containing two amidinium functional groups separated by a flexible 1,5-diphenoxypentane
spacer.7 Developed initially as an antiprotozoal agent, pentamidine currently finds
applications in both the treatment of protozoan diseases, such as Trypanosoma brucei

gambiense
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(West African trypanosomiasis), as well as systemic fungal infections caused by
Pneumocystis jirovecii, often seen in patients with HIV. Related compounds include
symmetrical bisamidines, (e.g., furimidazoline),8 developed principally as topoisomerase
inhibitors for cancer treatment. In addition to these biscationic compounds, other hydrazonecontaining and guanidine-containing molecules possess a range of promising biological
activities, including antitubercular,9,10 anti-HIV,11,12 anticonvulsant,13 anticancer,14 antiinflammatory,15,16 antimalarial,17,18 antibacterial,19,20 and antifungal activities.21,22
Recently, bis(N-amidinohydrazones) were reported to inhibit the calcium-dependent serine
endoprotease, furin, which activates immature proteins to their functional, mature forms.23
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Inspired by the above successes, we were intrigued by the possibility that biscationic
pharmacophores in either the bis(N-amidinohydrazones) or the N-(amidino)-N'-arylbishydrazone family with either a flexible or a rigid spacer would offer advantages in terms
of antibacterial and antifungal activities not found in the flexible bisamidines, as well as in
the hydrazone- and guanidine-containing molecules currently in the literature. To investigate
the potential of such compounds, we synthesized nine symmetrical bis(Namidinohydrazones) (3A-B and 4A,C-H) and eight asymmetrical N-(amidino)-N'-arylbishydrazones (7Aa-Ag and 8Aa) (Scheme 1). Further, we evaluated the antibacterial and
antifungal activities of these novel compounds against panels of bacterial strains (four
Gram-positive, six Gram-negative, and one mycobacterial) and seven Candida albicans
strains. Because the development of resistance represents a crucial problem in antimicrobial
drug development, we also established the potential for resistance development by bacteria
and fungi against these compounds. Additionally, we measured the production of reactive
oxygen species (ROS) of some of these compounds in yeast cells, determined their in vitro
cytotoxicity and their affinity for the human Ether-à-go-go-related gene (hERG) potassium
channel. The combination of testing new antimicrobial agents and early screening for
resistance and toxicity represents an avenue that may produce pharmacophores of potential
utility in the treatment of diseases.

2. Results and discussion
Author Manuscript

2.1. Design and chemical synthesis of biscationic compounds with two chemically
identical termini
The reported syntheses of biscationic compounds containing two identical termini bearing
guanidinium, amidinium, or pyridinium groups attached to aryl or alkyl spacers typically
involved the modification of spacers with termini bearing primary halides, carbonyl, or
nitrile groups.24-26 Alkylation of α,ω-dihaloalkanes, for example, with 2-aminopyridine led
to bis(2-aminopyridinium) salts.24 Modification of the nitrile group in 5-(4cyanophenyl)furan-2-carboxylic acid and completion of the spacer by linking the
carboxylate groups led to bisamidinium agents.27 In the same fashion, we modified the
Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.
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carbonyl groups in either bisaldehyde 1 or bisketone 2, which in some cases were in
regiochemically distinct positions in the spacer (e.g., 1B, 2B, 2H), with N-aminoguanidine
hydrochloride to obtain the biscationic products 3 and 4, respectively (Scheme 1A).
2.2. Design and chemical synthesis of biscationic compounds with chemically nonidentical termini

Author Manuscript

Synthetic approaches to bicationic agents with two chemically non-identical termini often
involved the construction of the spacer as the ultimate step. For example, the coupling of an
amidino-substituted naphthol with a guanidine-substituted benzoic acid secured biscationic
esters with an amidinium group at one terminus and a guanidinium group at the other.28 Our
approach differed from this strategy in that we utilized a stepwise, chemoselective
modification of bisaldehydes 1 or bisketones 2 in order to arrive at biscationic systems with
different cationic groups at each terminus. Condensations of one equivalent of Naminoguanidine hydrochloride with 1A and 2A led to the efficient production of
monosubstituted N-amidinohydrazones 5A and 6A, respectively. The hydrochloride salts of
these monocatioinic products were readily crystallized free from starting materials. The
subsequent treatment of 5A and 6A with N-arylhydrazines provided the desired, biscationic
agents 7Aa-Ag and 8Aa, respectively, which we describe as N-(amidino)-N'-arylbishydrazones (Scheme 1B). Cavallini described the monocationic N-amidinohydrazones as
antibacterial agents some years ago, but the range of organisms and MIC50 values were, in
general, unimpressive.29
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With these first generations of bis(N-amidinohydrazones) 3 and 4 and N-(amidino)-N'-arylbishydrazones 7 and 8 in hand, we aimed to answer the following eight apriori questions in
terms of structure-activity-relationship (SAR). We included the numbers of the compounds
used to answer these questions into parentheses following the questions. The eight questions
are as follows: (i) are linkers comprised of only one aromatic ring sufficient to confer
antimicrobial activity? (compounds 4G and 4H); (ii) is the presence of methyl groups on the
carbons alpha to the linker beneficial for antimicrobial activity? (compounds 3A versus 4A,
and 7Aa versus 8Aa); (iii) how does the substitution pattern of the biphenyl linker affect
antimicrobial activity? (compounds 3A and 3B); (iv) how does the length of the flexible
linear alkyl spacer between the two phenyl rings affect antimicrobial activity? (compounds
4A, 4C, and 4D); (v) is the introduction of rigidity in the linker beneficial for antimicrobial
activity? (compound 4C versus 4F); (vi) is the presence of an oxygen atom in the linker
beneficial for antimicrobial activity? (compound 4C versus 4E); (vii) how does the identity
of the substituent, when located at the same position on the aryl ring of the side chain, affect
antimicrobial activity? (compounds 7Aa versus 7Ab, 7Ac versus 7Ad versus 7Ae, and 7Af
versus 7Ag); and finally, (viii) how does the substitution pattern of the aryl ring (ortho
versus para-monosubstituted versus ortho,para-disubstituted) affect antimicrobial activity?
(compounds 7Aa versus 7Ad versus 7Ag).
2.3. Antibacterial activity
To determine if our novel bis(N-amidinohydrazones) and N-(amidino)-N'-arylbishydrazones displayed antibacterial activity, we first evaluated compounds 3A-8Aa against
a panel of Gram-positive (4 strains), Gram-negative (6 strains), and one mycobacterial strain
Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.
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in a concentration range of 0.5-500 μM (Table 1). We used the aminoglycoside amikacin
(AMK), the β-lactam ampicillin (AMP), and the fluoroquinolone ofloxacin (OFX) as
positive controls. In general, the novel compounds displayed excellent (MIC values ≤0.5-7.8
μM), intermediate (also referred to as moderate) (15.6-31.3 μM), or low (also referred to as
poor) (62.5-≥500 μM) antibacterial activity against the bacterial strains tested. It is important
to note that these MIC value ranges are used from here on to qualitatively described all
compounds tested, including the positive controls.

Author Manuscript

Overall, when analyzing the MIC data obtained against the Gram-positive bacterial strains
(strains A-D), we note that most of the novel bis(N-amidinohydrazones) (3A,B, 4C,D, 4F)
and N-(amidino)-N'-aryl-bishydrazones (7Aa-Ad, and 7Af-Ag) showed excellent
antibacterial activity against Listeria monocytogenes ATCC 19115 (strain B, Lmo) (MIC
<0.5-7.8 μM), methicillin-resistant Staphylococcus aureus (strain C, MRSA) (MIC = 1.0-7.8
μM), and vancomycin-resistant enterococcus (strain D, VRE) (MIC = 1.0-7.8 μM). All of the
novel compounds displayed poor activity against Bacillus subtilis 168 (strain A, Bsu), with
the exception of compound 4F, which displayed excellent activity (MIC = 7.8 μM) against
this strain. Likewise, compound 7Ae exhibited excellent antibacterial activity against L.
monocytogenes ATCC 19115 (strain B, Lmo; MIC = 7.8 μM) and VRE (strain D; MIC =
2.0-3.9 μM), but only moderate antibacterial activity against B. subtilis 168 (strain A, Bsu;
MIC = 31.3 μM) and MRSA (strain C; MIC = 15.6 μM), respectively. In general,
compounds 4A, 4E (except against strain D, VRE), 4G, 4H, and 8Aa (except against strain
D) showed poor antibacterial activity (MIC = 62.5-≥500 μM) against all four Gram-positive
bacterial strains tested. Overall, compound 4F was the most active against Gram-positive
bacteria.

Author Manuscript
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On the other hand, the majority of the novel compounds remained inactive against most of
the Gram-negative bacterial strains that we tested with MIC values ranging from 62.5->500
μM. As one of several exceptions, compound 4A exhibited excellent activity against P.
aeruginosa ATCC 27853 (strain I, Pae; MIC = 2.0 μM) and moderate activity against
Klebsiella pneumoniae ATCC 27736 (strain H, Kpn; MIC = 15.6 μM). Similarly, compound
4F also displayed excellent antibacterial activities against Pae strain I (MIC = 1.0-2.0 μM)
and S. enterica ATCC 14028 (strain J, Sen; MIC = 3.9 μM), as well as moderate to low
activity against Kpn strain H (MIC = 31.3-62.5 μM). Additionally, 7Ae showed only
moderate antibacterial activities against Kpn strain H (MIC = 15.6-31.3 μM), strain I (MIC
= 31.3-62.5 μM), and Sen strain J (MIC = 15.6 μM). Compounds 3B, 4C-D, 4F, 7Aa-Ad,
and 7Af-Ag exhibited excellent antibacterial activity (MIC = 1.0-3.9 μM) against M.
smegmatis MC2-155 (strain K, Msm), whereas compounds 4H and 7Ae showed only
moderate activity (MIC = 15.6-31.3 μM) and compounds 3A, 4A, 4E, 4G, and 8Aa showed
low activity (MIC = 125->500 μM) against this mycobacterial strain. It is noteworthy that
when compared to clinically relevant antibacterial drugs, such as AMK (MIC = 3.9-125
μM), AMP (MIC ≥250 μM), and OFX (MIC ≤0.5-31.3 μM), the novel compounds showed
either superior or comparable antibacterial activity against all bacterial strains tested.
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Having established the antibacterial activity profile of the novel bis(N-amidinohydrazones)
and N-(amidino)-N'-arylbishydrazones, we next determined their antifungal activity against
a panel of seven Candida albicans strains using a concentration range of 0.5-31.3 μg/mL
(Table 2). We used the common antifungal agent amphotericin B (AmB) as a positive
control testing in the same concentration range of 0.5-31.3 μg/mL. For antifungal activity,
we use the following descriptors: excellent (MIC = 0.5-3.9 μg/mL), moderate (MIC =
7.8-15.6 μg/mL), and poor (MIC = 31.3 μg/mL). We found that compounds 3B, 4F, 7Aa,
7Ab, and 7Af exhibited excellent antifungal activities against all fungal strains tested (MIC
= 1.0-3.9 μg/mL), with 4F being overall the most active. The only exception to the
aforementioned statement was 7Af, which displayed only moderate activity against C.
albicans ATCC 90819 (MIC = 7.8 μg/mL). Similarly, compound 4A also displayed excellent
antifungal activities (MIC = 2.0-3.9 μg/mL) against most strains, except against C. albicans
ATCC 1003 (MIC = 7.8 μg/mL) and C. albicans ATCC 1237 (MIC = 31.3 μg/mL).
Compounds 7Ad, 7Ae, 7Ag, and 8Aa showed only moderate fungal growth inhibition (MIC
= 7.8-15.6 μg/mL) against the majority of the fungal strains, with the exception of C.
albicans ATCC 64124 (MIC = 31.3 μg/mL for 7Ae, 7Ag, and 8Aa), C. albicans ATCC
90819 (MIC = 31.3 μg/mL for 7Ag), C. albicans ATCC 1003 (MIC = 3.9 μg/mL for 7Ad)
and C. albicans ATCC 2310 (MIC = 3.9 μg/mL for 7Ad). Compounds 7Ac also exhibited
excellent growth inhibition against most of the fungal strains tested, except against C.
albicans ATCC 10231 (moderate activity, MIC = 7.8 μg/mL) and C. albicans ATCC 64124
(poor activity, MIC = 31.3 μg/mL). Just as observed against all bacterial strains, compounds
4G and 4H displayed no activity (MIC ≥31.3 μg/mL) against all fungal strains tested. It is
important to emphasize that most of our bis(N-amidinohydrazones) and N-(amidino)-N'aryl-bishydrazones displayed either superior or comparable antifungal activities against the
majority of the fungal strains tested, when compared to the clinically-relevant antifungal
agent, AmB (MIC = 2.0-3.9 μg/mL).
2.5. SAR analysis
Using the antibacterial and antifungal results presented above (Tables 1 and 2), we addressed
the eight apriori questions posed:

Author Manuscript

(i)

Are linkers comprised of only one aromatic ring sufficient to confer
antimicrobial activity? We concluded that bis(N-amidinohydrazones) with
linkers comprised of a single phenyl ring, regardless of its substitution pattern
(para or meta, as in compounds 4G and 4H, respectively), displayed
insufficient activity as antimicrobial agents to warrant further study of their
antibacterial or antifungal activity.

(ii)

Is the presence of methyl groups on the carbons alpha to the linker beneficial
for antimicrobial activity? Comparing the MIC values of compounds 3A and
4A as well as 7Aa and 8Aa, which only differ by the absence or presence of a
methyl group on the carbons alpha to the phenyl rings, led us to conclude that
the methyl group was detrimental to the antibacterial activity of these
compounds. However, the presence of the methyl group appeared beneficial in

Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.
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terms of antifungal activity. Compound 4A was overall a much more active
antifungal agent than compound 3A.
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(iii)

How does the substitution pattern of the biphenyl linker affect antimicrobial
activity? When evaluating compounds 3A and 3B, the antibacterial MIC values
were similar in all cases, except against strain K where the MIC value for
compound 3B (MIC = 1 μM) was 500 times lower than that for compound 3A
(MIC >500 μM). From these data, we deduced that the substitution pattern of
the biphenyl linker had minimal effect on antibacterial activity. However, we
found the substitution pattern of the biphenyl linker to have a substantial effect
on antifungal activity. For example, compound 3B was a much more active
antifungal agent than compound 3A.

(iv)

How does the length of the flexible linear alkyl spacer between the two phenyl
rings affect antimicrobial activity? When comparing the MIC values of
compounds 4A, 4C, and 4D, again we observed opposing trends in
antibacterial and antifungal activities. Longer flexible alkyl linkers between the
two phenyl rings correlated with a decrease in antibacterial MIC values, but
correlated with an increase in antifungal MIC values.

(v)

Is the introduction of rigidity in the linker beneficial for antimicrobial activity?
By contrasting the MIC value profile of compound 4C containing a flexible
linker to that of compound 4F containing a rigid linker, we concluded that
introducing rigidity in the linker was overall beneficial for antimicrobial
activity.

(vi)

Is the presence of an oxygen atom in the linker beneficial for antimicrobial
activity? A comparison of the MIC value profiles of compounds 4C and 4E
indicated that replacing the methylene bridging the two phenyl groups of the
linker by an oxygen atom had no effect on antifungal activity, but was
detrimental to antibacterial activity.

(vii)

How does the identity of the substituent, when located at the same position on
the aryl ring of the side chain, affect antimicrobial activity? By comparing
compounds 7Aa-7Ag, we observed that the nature of the substituent in the
ortho position of the mono-substituted aryl group of compounds 7Aa and 7Ab
did not affect antibacterial or antifungal activity, whereas the nature of the
substituent in the para position of the mono-substituted aryl group of
compounds 7Ac-7Ae had opposing effects on antibacterial (CN > halogen) and
antifungal (halogen > CN) activity. We also observed that the o,p-difluorinated
and o,p-dichlorinated aryl moieties of compounds 7Af and 7Ag had similar
overall antibacterial activity, but different antifungal activity, in which the o,pdifluorinated group possessed improved antifungal activity.

(viii)

How does the substitution pattern of the aryl ring (ortho versus paramonosubstituted versus ortho,para-disubstituted) affect antimicrobial activity?
Finally, comparison of the activity resulting from different chlorination
patterns in compounds 7Aa (ortho), 7Ad (para), and 7Ag (o,p-diCl), revealed

Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.
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minimal effects on antibacterial activity, but substantial effects on antifungal
activity. The o-Cl N-(amidino)-N'-aryl-bishydrazone was superior to the p-Cl
analogue, which in turn was much better than o,p-diCl analogue. In summary,
the similarity and differences in the trends observed in this promising,
preliminary SAR will be used to lay the foundation for the future discovery of
compounds capable of selectively targeting either bacteria or fungi.
2.6. Development of bacterial and fungal resistance studies

Author Manuscript
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The emergence of antibiotic resistance by microbes is an inevitable process; however, the
frequency at which resistance develops varies from one antibiotic to another. It is critical to
assess the ability of new antimicrobials to evade, as long as possible, the development of
bacterial and fungal resistance early in the drug discovery process. To establish if the bis(Namidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones evade resistance in bacteria, we
first performed a multi-step resistance selection experiment with compounds 4D, 4F, and
7Aa as well as with AMK as a reference drug against four bacterial strains (Figure 1). L.
monocytogenes ATCC 19115 (strain B, Lmo), MRSA (strain C), VRE (strain D), and P.
aeruginosa ATCC 27853 (strain I, Pae) were exposed to sub-inhibitory concentrations of
compounds 4D, 4F, 7Aa, and AMK, and were sub-cultured for 15 serial passages to
determine if an increase in MIC values occurred for each compound against the strains
tested. L. monocytogenes ATCC 19115 (strain B, Lmo), MRSA (strain C), VRE (strain D),
and P. aeruginosa ATCC 27853 (strain I, Pae) did not develop resistance to compound 4F,as
demonstrated by the one-fold increase in MIC values after 15 serial passages. Likewise,
strains B (Lmo) and D (VRE) did not develop resistance to compound 7Aa, but strains C
(MRSA) and I (Pae) developed resistance to this compound after twelve serial passages. In
contrast, we observed the rapid development of resistance to compound 4D in strains C
(MRSA) and D (VRE)with a 16-fold increase in MIC values after fifteen serial passages.
This development of resistance against compound 4D was observed also in strains B (Lmo)
and I (Pae), where increases in relative MIC values by 8- and 4-folds, respectively, were
observed after 15 passages. Interestingly, in strains D (VRE) and I (Pae), resistance to the
control antibiotic, AMK, was observed also after 3 and 5 passages, respectively; whereas in
strains C (MRSA) and B (Lmo), resistance developed after 12 and 15 passages, respectively.
Overall, these results indicate that there is a low probability of emergence of resistance to
these promising novel biscationic compounds 4D, 4F, and 7Aa.
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We next investigated the development of drug resistance in C. albicans ATCC 10231 to our
best antifungal compounds 7Aa and 4F, and we found that C. albicans ATCC 10231 did not
to develop drug resistance to either 7Aa or 4F, despite repeated treatments with sub-MIC
drug concentrations. Only a slight 2-fold shift in MIC values was observed after 13
passages. These results also suggest the low probability of onset of drug resistance by fungi
to these novel compounds.
2.7. Measurement of ROS induction in fungal cells
Various antifungal drugs, such as AmB and miconazole, as well as novel antifungal agents,
were shown to mediate their inhibitory effect by inducing intracellular ROS production.30-32
Universally, eukaryotic cells produce basal amount of ROS in mitochondria as a byproduct
Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.
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of cellular metabolism. In response, the cellular enzymatic antioxidants, including
superoxide dismutase and glutathione peroxidase, scavenge ROS in cells. However,
overproduction of deleterious ROS perturbs the delicate, intracellular equilibrium between
ROS production and scavenging, and the result is cellular damage.
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In order to investigate the ability of compounds 4F and 7Aa to alter ROS production in C.
albicans ATCC 10231 (strain A), we performed a fluorescent-based assay using a 2',7'dichlorodihydrofluorescein diacetate (DCFH-DA) dye.33 We found that treatment of C.
albicans ATCC 10231 (strain A) with compounds 4F and 7Aa at their 1× and 2× MIC values
increased intracellular ROS production in this fungal strain (Figure 2). As expected, the
H2O2 positive control (at 1 mM) also induced ROS production in yeast cell, whereas no
ROS induction was observed with untreated yeast cells (negative control). Although it
remains to be determined if ROS production is critical for growth inhibition and death of
yeast cells, these results suggest one direction for future mechanistic exploration, which is
outside of the scope of the current proof-of-principle exploration for the first generations of
bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones as antimicrobials.
2.8. Cytotoxicity
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Another important aspect to consider during the development of antimicrobial agents is their
potential toxicity towards mammalian cells. Having established the potent antimicrobial
activities of the novel bis(N-amidinohydrazones) and N-(amidinohydrazones)-N'-arylbishydrazones against bacteria and fungi, we determined the toxicity profile of these
compounds against two mammalian cell lines (A549 and BEAS-2B; Figure 3) and measure
the IC50 values for these compounds (Table 3). The majority of the novel compounds
showed concentration-dependent toxicity with IC50 values of 1.7-6.7 μg/mL. Compounds
3B, 7Ac, 7Ad, and 7Af, with excellent antibacterial MIC values of <0.4-3.3 μg/mL,
displayed IC50 values of 4.4-13.9 μg/mL against both mammalian cell lines. It is important
to note that compounds 7Ac and 7Af also displayed excellent antifungal MIC values,
indicating that these compounds are important leads for future evaluation.
2.9. hERG inhibition assay
The hERG encodes a voltage gated potassium channel that plays an essential role in
regulating hearth rhythm.34 Inhibition of the hERG channel disrupts the heart rhythm and
may lead to cardiac death. Recently, drugs (e.g., terfendadine and cisapride) were withdrawn
from the market due to their interaction with the hERG channel.35 Currently, the U.S. Food
and Drug Administration (FDA) and the European Medicines Agency (EMA) require
evaluation at hERG for drug candidates.
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We performed a [3H]-dofetilide competition binding assay using HEK-293 cell membranes
stably expressing the hERG channel to evaluate the activity of our most potent bis(Namidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones at hERG (Figure 4).
Compounds exhibiting IC50 values of >10 μM are considered to have low affinity for the
hERG channel. Compounds displaying IC50 values in the range of 1-10 μM are considered
to have moderate affinity, whereas compounds exhibiting IC50 values of <1 μM are
considered to have high affinity for the hERG channel.36 The majority of the novel
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compounds displayed IC50 values within the acceptable range of 1-10 μM (Figure 4).
Although compound 7Ab displayed excellent antifungal activities (2-3.9 μg/mL), it
exhibited in vitro mammalian cell toxicity and was found to potently interact with the hERG
channel (IC50 = 0.44 ± 0.10 μM), suggesting that the o-bromophenyl substituent is an
unfavorable structural feature. However, the p-fluorophenyl and the 2,4-difluorophenyl
groups in compounds 7Ac and 7Af displayed only moderate interaction with hERG (IC50 =
3.29 ± 0.63 μM and 2.24 ± 0.70 μM, respectively). Strikingly, both of these compounds
displayed excellent antifungal activities and also exerted low mammalian cell toxicity.
Similarly, compounds 4F and 7Aa displayed moderate affinity for hERG (IC50 = 1.12 ± 0.32
μM and 1.14 ± 0.27 μM, respectively); however, they displayed some toxicity against
mammalian cells. Therefore, we concluded that compounds 7Ac and 7Af are the most
promising N-(amidino)-N'-aryl-bishydrazone compounds.

Author Manuscript

3. Conclusions
In summary, we discovered nine bis(N-amidinohydrazones) and eight N-(amidino)-N'-arylbishydrazones as first-generation antibacterial and antifungal agents. These compounds
displayed low potential for the development of resistance and were found to induce ROS
production in a C. albicans strain. They also were found to display reasonable toxicity
profiles against two mammalian cell lines as well as acceptable levels of interaction with
hERG channels. However, as these compounds display both antibacterial and antifungal
activity, it is possible that they aim at a target shared by prokaryotes and eukaryotes and
potentially display lower selectivity. However, in light of our SAR study, we conclude that
compounds 4F, 7Ac, and 7Af, which showed the most promise, warrant further
optimization. Such studies are currently underway in our laboratories.
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4. Experimental section / Supplementary material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 1.

Synthetic scheme for the preparation of A. the bis(N-amidinohydrazones) and B. N(amidino)-N'-aryl-bishydrazones.

Author Manuscript
Bioorg Med Chem. Author manuscript; available in PMC 2018 January 01.

Shrestha et al.

Page 14

Author Manuscript
Author Manuscript

Figure 1.

Changes in MIC values of L. monocytogenes ATCC 19115 (strain B), MRSA (strain C),
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I) treated with AMK (green), 7Aa
(purple), 4F (blue), 4D (orange), as well as C. albicans ATCC 10231 treated with AmB
(yellow), 7Aa (purple), and 4F (blue) over 15 cycles. Numbers above the bars represent the
passage when either bacterial or fungal cells developed resistance.
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Effect of compounds 4F and 7Aa on intracellular ROS production by C. albicans ATCC
10231. Yeast cells were treated in the absence of drug (negative control), 1 mM of H2O2
(positive control), or 4F and 7Aa, at 1× and 2× respective MIC values for 1 h at 35 °C. After
staining with DCFH-DA (20 μg/mL), the samples were analyzed using a Zeiss Axovert
200M fluorescence microscope.
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Figure 3.

Mammalian cell cytotoxicity of selected bis(N-amidinohydrazones) and N-(amidino)-N'aryl-bishydrazones, as well as AmB (as a control) against A. A549 cell line and B.
BEAS-2B cell line.
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Figure 4.

IC50 curves for hERG interaction by representative bis(N-amidinohydrazones) and N(amidino)-N'-aryl-bishydrazones along with a table (bottom right) summarizing these IC50
values.
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MIC values in μg/mL and (μM) for compounds 3A,B, 4A,C-H, 7Aa-Ag, and 8Aa against various bacterial strains.
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MIC values in μg/mL and (μM) for compounds 3A,B, 4A,C-H, 7Aa-Ag, and 8Aa against various C. albicans
strains.
C. albicans ATCC strain #
Cpd

a

b

c

c

b

b

b
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1003

1237

2310

2876

10231

64124

90819

AmB

3.9 (4.2)

3.9 (4.2)

3.9 (4.2)

3.9 (4.2)

3.9 (4.2)

2.0-3.9 (2.1-4.2)

2.0 (2.1)

3A

7.8 (19.7)

15.6 (39.5)

>31.3 (>79.2)

7.8 (19.7)

15.6 (39.5)

>31.3 (>79.2)

>31.3 (>79.2)

3B

3.9 (9.9)

3.9 (9.9)

3.9 (9.9)

3.9 (9.9)

3.9 (9.9)

3.9 (9.9)

3.9 (9.9)

4A

7.8 (18.4)

>31.3 (>73.9)

3.9 (9.2)

2.0 (4.7)

2.0-3.9 (4.7-9.2)

2.0 (4.7)

3.9 (9.2)

4C

7.8 (17.8)

7.8 (17.8)

7.8 (17.8)

3.9 (8.9)

7.8 (17.8)

7.8 (17.8)

7.8 (17.8)

4D

15.6 (34.6)

15.6 (34.6)

31.3 (69.3)

3.9 (8.6)

7.8 (17.3)

>31.3 (>69.3)

7.8 (17.3)

4E

7.8 (17.8)

7.8 (17.8)

7.8 (17.8)

3.9 (8.9)

7.8 (17.8)

7.8 (17.8)

7.8 (17.8)

4F

1.0 (2.3)

2.0 (4.6)

1.0 (2.3)

1.0 (2.3)

1.0-2.0 (2.3-4.6)

1.0 (2.3)

2.0 (4.6)

4G

>31.3 (>90.1)

>31.3 (>90.1)

>31.3 (>90.1)

>31.3 (>90.1)

>31.3 (>90.1)

31.3 (90.1)

>31.3 (>90.1)

4H

>31.3 (>90.1)

31.3 (90.1)

31.3 (90.1)

7.8 (22.5)

>31.3 (>90.1)

>31.3 (>90.1)

>31.3 (>90.1)

7Aa

2.0 (4.6)

3.9 (9.2)

2.0 (4.6)

2.0 (4.6)

2.0 (4.6)

3.9 (9.2)

2.0 (4.6)

7Ab

2.0 (4.1)

3.9 (8.3)

3.9 (8.3)

3.9 (8.3)

2.0 (4.1)

3.9 (8.3)

3.9 (8.3)

7Ac

2.0 (4.7)

7.8 (19.0)

3.9 (9.5)

3.9 (9.5)

7.8 (19.0)

31.3 (76.2)

3.9 (9.5)

7Ad

3.9 (9.1)

15.6 (36.5)

3.9 (9.1)

7.8 (18.3)

7.8 (18.3)

15.6 (36.5)

7.8 (18.3)

7Ae

7.8 (18.7)

15.6 (37.3)

15.6 (37.3)

15.6 (37.3)

15.6 (37.3)

31.3 (74.9)

15.6 (37.3)

7Af

2.0 (4.5)

3.9 (9.1)

3.9 (9.1)

3.9 (9.1)

1.0 (2.3)

3.9 (9.1)

7.8 (18.2)

7Ag

7.8 (16.8)

15.6 (33.8)

7.8 (16.8)

15.6 (33.8)

7.8 (16.8)

31.3 (67.8)

31.3 (67.8)

8Aa

15.6 (34.3)

15.6 (34.3)

15.6 (34.3)

15.6 (34.3)

15.6 (34.3)

31.3 (68.7)

15.6 (34.3)

Author Manuscript

Control antifungal agent: AmB = amphotericin B.

a

These antifungal MIC values were determined originally in μg/mL using a range of 0.5 to 31.3 μg/mL. The values in μM into parentheses are
presented for comparison with the antibacterial MIC values, which were determined originally in μM.

b

Indicates strains that are resistant to FLC, ITC, and VOR according to ATCC.

c
Indicates strains that are susceptible to FLC, ITC, and VOR according to ATCC.
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Table 3

Author Manuscript

The cytotoxicity (IC50, μg/mL) of selected bis(N-amidinohydrazones) and N-(amidino)-N′-aryl-bishydrazones
against A549 and BEAS-2B cell lines. Values are presented as mean ± SDEV.
Mammalian cell line

Author Manuscript

Cpd

A549

BEAS-2B

AmB

18.2 ± 4.5

17.7 ± 6.4

3A

6.6 ± 1.7

3.0 ± 0.7

3B

13.9 ± 4.1

5.7 ± 1.8

4A

6.3 ± 2.2

1.7 ± 0.5

4C

4.3 ± 1.3

2.9 ± 0.9

4D

2.9 ± 0.9

1.8 ± 0.6

4E

3.9 ± 0.9

2.9 ± 0.9

4F

2.5 ± 1.4

1.8 ± 0.6

4H

31.2 ± 7.2

33.0 ± 4.6

7Aa

2.8 ± 0.9

2.3 ± 1.0

7Ab

6.7 ± 2.3

3.4 ± 1.3

7Ac

4.4 ± 1.4

6.0 ± 1.2

7Ad

4.9 ± 1.1

6.0 ± 1.1

7Ae

4.2 ± 1.4

1.9 ± 0.8

7Af

4.8 ± 1.3

5.8 ± 1.2
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